Methylphenidate modified release as treatment of MS-associated fatigue.
What it found
The trial ended early for another reason (see below).
What was tested
Treatment tested
- Methylphenidate
Dopamine transporter inhibitor|Norepinephrine transporter inhibitor
What it measured
Main measures
Improvement (baseline vs. 6 weeks) of fatigue as assessed by Fatigue Severity Scale
Fatigue
Other measures (1)
Improvement of fatigue (baseline vs. 6 weeks) as assessed by modified
Fatigue
Who could take part
Relapsing MS
Inclusion: Diagnosis of multiple sclerosis (relapsing remitting, progressive Exclusion: Known allergy or hypersensitivity to Methylphenidate or any of its
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The goal of our study is to determine the efficacy of methylphenidate in reducing fatigue in subjects with Multiple sclerosis. The question of whether MS‐associated fatigue improves after 6 weeks of methylphenidate therapy compared to baseline as measeured by Fatigue severity scale comprises the primary objective of our study.
Loading reviews and guidelines…
Related trials
- MODAFIMS
Phase 2 · Recruiting
Still running
- Fatigue Treatment Using Provigil
Not a drug-phase study · Status unknown
No result found
- Combination Therapy (Provigil + Avonex) to Treat Cognitiv…
Not a drug-phase study · Status unknown
No result found
History
Started
Nov 2012
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error